<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00839917</url>
  </required_header>
  <id_info>
    <org_study_id>V221-023</org_study_id>
    <secondary_id>2009_538</secondary_id>
    <nct_id>NCT00839917</nct_id>
  </id_info>
  <brief_title>A Study of ProQuad™ in Healthy Children in Korea (V221-023)</brief_title>
  <official_title>A Multicenter, Randomized, Open-Label Study to Compare the Immunogenicity, Safety, and Tolerability of Measles, Mumps, Rubella, and Varicella of Combination Vaccine ProQuad With Concomitant Administration of M-M-R II and VARIVAX in Healthy Korean Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Merck Sharp &amp; Dohme Corp.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare ProQuad™ and concomitant administration of M-M-R™ II and Varivax™
      with respect to immunogenicity, safety and tolerability. The primary hypothesis to be tested
      is that the antibody response rates to measles, mumps, rubella, and varicella 6 weeks after
      vaccination with ProQuad™ will be non-inferior to the antibody response rates after
      vaccination with concomitant M-M-R™ II and Varivax™.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Study terminated early because of insufficient enrollment before expiration date of the
    investigational vaccine lot
  </why_stopped>
  <start_date>February 2008</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Measles Antibody Levels ≥255 mIU/mL</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Antibody response to measles at 6 weeks after vaccination for participants initially seronegative (&lt;255 mIU/mL) to measles at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Mumps Antibody Levels ≥10 Mumps Antibody Units/mL</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Antibody response to mumps at 6 weeks after vaccination for participants initially seronegative (&lt;10 units/mL) to mumps at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Rubella Antibody Levels ≥10 IU/mL</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Antibody response to rubella at 6 weeks after vaccination for participants initially seronegative (&lt;10 IU/mL) to rubella at baseline</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Participants With Varicella-zoster Virus (VZV) Antibody Levels ≥5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Antibody response to VZV at 6 weeks after vaccination for participants initially seronegative (&lt;5 gpELISA units/mL) to VZV at baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Measles Antibodies</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Mean measles antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;255 mIU/mL) to measles at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Mumps Antibodies</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Mean mumps antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;10 Units/mL) to mumps at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of Rubella Antibodies</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Mean rubella antibody response at 6 weeks postvaccination for participants initially seronegative (&lt;10 IU/mL) to rubella at baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Geometric Mean Titer of VZV (gpELISA) Antibodies</measure>
    <time_frame>6 weeks postvaccination</time_frame>
    <description>Mean VZV antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;5 gpELISA Units/mL) to VZV at baseline</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Measles-like Rash</measure>
    <time_frame>Through 6 weeks postvaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Varicella-like Rash</measure>
    <time_frame>Through 6 weeks postvaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Rubella-like Rash</measure>
    <time_frame>Through 6 weeks postvaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Zoster-like Rash</measure>
    <time_frame>Through 6 weeks postvaccination</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Any Systemic Adverse Experience</measure>
    <time_frame>Through 6 weeks postvaccination</time_frame>
    <description>An adverse experience is defined as any unfavorable and unintended change in the
structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. A systemic adverse experience is any adverse experience other than injection-site adverse experiences.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Injection-site Adverse Experiences</measure>
    <time_frame>Through 6 weeks postvaccination</time_frame>
    <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. An injection-site adverse experience is an adverse experience that occurs at the injection site only.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Injection-site Adverse Experiences</measure>
    <time_frame>Through 5 days postvaccination</time_frame>
    <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. An injection-site adverse experience is an adverse experience that occurs at the injection site only.</description>
  </other_outcome>
  <other_outcome>
    <measure>Percentage of Participants With Fever (≥101.0°F [38.3°C] Axillary or ≥103.0°F [39.4°C] Rectal)</measure>
    <time_frame>Through 6 weeks postvaccination</time_frame>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Measles</condition>
  <condition>Mumps</condition>
  <condition>Rubella</condition>
  <condition>Varicella</condition>
  <arm_group>
    <arm_group_label>ProQuad™</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>M-M-R™ II and Varivax™</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Measles, Mumps, Rubella and Varicella (Oka-Merck) Virus Vaccine Live (ProQuad™)</intervention_name>
    <description>Single administration of 0.5 mL subcutaneous injection</description>
    <arm_group_label>ProQuad™</arm_group_label>
    <other_name>V221</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>M-M-R™ II and Varivax™</intervention_name>
    <description>Single administration of 0.5 mL subcutaneous injection</description>
    <arm_group_label>M-M-R™ II and Varivax™</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject is in good health

          -  Subject has a negative clinical history for measles, mumps, rubella, varicella and
             zoster

        Exclusion Criteria:

          -  Subject has previously received measles, mumps, rubella and/or varicella vaccine,
             either alone or in any combination

          -  Subject has any congenital or acquired immune deficiency, neoplastic disease or
             depressed immunity

          -  Subject has a history of seizure disorder

          -  Subject had exposure to measles, mumps, rubella, varicella and/or zoster in the last 4
             weeks

          -  Subject has received an inactivated vaccine within the past 14 days

          -  Subject has received a live vaccine within the past 30 days

          -  Subject has received immune globulin within the past 5 months

          -  Subject has a recent history of fever (within the last 72 hours)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Months</minimum_age>
    <maximum_age>23 Months</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Monitor</last_name>
    <role>Study Director</role>
    <affiliation>Merck Sharp &amp; Dohme Corp.</affiliation>
  </overall_official>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>MedWatch - FDA maintained medical product safety Information</description>
  </link>
  <link>
    <url>http://www.merck.com/product/patients_caregivers/home.html</url>
    <description>Merck: Patient &amp; Caregiver U.S. Product Web Site</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2009</study_first_submitted>
  <study_first_submitted_qc>February 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 10, 2009</study_first_posted>
  <results_first_submitted>September 7, 2012</results_first_submitted>
  <results_first_submitted_qc>September 7, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 10, 2012</results_first_posted>
  <last_update_submitted>March 15, 2017</last_update_submitted>
  <last_update_submitted_qc>March 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 12, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Measles</keyword>
  <keyword>Mumps</keyword>
  <keyword>Rubella</keyword>
  <keyword>Varicella</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Measles</mesh_term>
    <mesh_term>Chickenpox</mesh_term>
    <mesh_term>Herpes Zoster</mesh_term>
    <mesh_term>Rubella</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>http://www.merck.com/clinical-trials/pdf/Merck%20Procedure%20on%20Clinical%20Trial%20Data%20Access%20Final_Updated%20July_9_2014.pdf
http://engagezone.msd.com/ds_documentation.php</ipd_description>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The study was planned to enroll 360 participants; however the study was terminated early because it was not possible to complete enrollment before expiration of the investigational vaccine lot</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>ProQuad™</title>
          <description>Single subcutaneous 0.5 mL vaccination</description>
        </group>
        <group group_id="P2">
          <title>M-M-R™ II and Varivax™</title>
          <description>Single subcutaneous 0.5 mL vaccination</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="13"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="12">Study completers were randomized participants who received study vaccination and had follow-up data</participants>
                <participants group_id="P2" count="16">Study completers were randomized participants who received study vaccination and had follow-up data</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Did not receive vaccine</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ProQuad™</title>
          <description>Single subcutaneous 0.5 mL vaccination</description>
        </group>
        <group group_id="B2">
          <title>M-M-R™ II and Varivax™</title>
          <description>Single subcutaneous 0.5 mL vaccination</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="13"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>12 to 15 months</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Measles Antibody Levels ≥255 mIU/mL</title>
        <description>Antibody response to measles at 6 weeks after vaccination for participants initially seronegative (&lt;255 mIU/mL) to measles at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Measles Antibody Levels ≥255 mIU/mL</title>
          <description>Antibody response to measles at 6 weeks after vaccination for participants initially seronegative (&lt;255 mIU/mL) to measles at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="74.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="87.5" lower_limit="52.9" upper_limit="99.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Mumps Antibody Levels ≥10 Mumps Antibody Units/mL</title>
        <description>Antibody response to mumps at 6 weeks after vaccination for participants initially seronegative (&lt;10 units/mL) to mumps at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Mumps Antibody Levels ≥10 Mumps Antibody Units/mL</title>
          <description>Antibody response to mumps at 6 weeks after vaccination for participants initially seronegative (&lt;10 units/mL) to mumps at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="74.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="68.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Rubella Antibody Levels ≥10 IU/mL</title>
        <description>Antibody response to rubella at 6 weeks after vaccination for participants initially seronegative (&lt;10 IU/mL) to rubella at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rubella Antibody Levels ≥10 IU/mL</title>
          <description>Antibody response to rubella at 6 weeks after vaccination for participants initially seronegative (&lt;10 IU/mL) to rubella at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="100.0" lower_limit="74.1" upper_limit="100.0"/>
                    <measurement group_id="O2" value="100.0" lower_limit="68.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Varicella-zoster Virus (VZV) Antibody Levels ≥5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL</title>
        <description>Antibody response to VZV at 6 weeks after vaccination for participants initially seronegative (&lt;5 gpELISA units/mL) to VZV at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Varicella-zoster Virus (VZV) Antibody Levels ≥5 Glycoprotein Enzyme-linked Immunosorbent Assay (gpELISA) Units/mL</title>
          <description>Antibody response to VZV at 6 weeks after vaccination for participants initially seronegative (&lt;5 gpELISA units/mL) to VZV at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="90.0" lower_limit="60.6" upper_limit="99.5"/>
                    <measurement group_id="O2" value="100.0" lower_limit="68.8" upper_limit="100.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Measles Antibodies</title>
        <description>Mean measles antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;255 mIU/mL) to measles at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Measles Antibodies</title>
          <description>Mean measles antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;255 mIU/mL) to measles at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>mIU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5270.7" lower_limit="3952.0" upper_limit="7029.3"/>
                    <measurement group_id="O2" value="3516.2" lower_limit="1188.8" upper_limit="10396.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Mumps Antibodies</title>
        <description>Mean mumps antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;10 Units/mL) to mumps at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Mumps Antibodies</title>
          <description>Mean mumps antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;10 Units/mL) to mumps at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>Units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="159.2" lower_limit="93.1" upper_limit="271.8"/>
                    <measurement group_id="O2" value="104.4" lower_limit="59.2" upper_limit="183.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of Rubella Antibodies</title>
        <description>Mean rubella antibody response at 6 weeks postvaccination for participants initially seronegative (&lt;10 IU/mL) to rubella at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of Rubella Antibodies</title>
          <description>Mean rubella antibody response at 6 weeks postvaccination for participants initially seronegative (&lt;10 IU/mL) to rubella at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>IU/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.8" lower_limit="69.6" upper_limit="160.5"/>
                    <measurement group_id="O2" value="147.1" lower_limit="105.6" upper_limit="204.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Geometric Mean Titer of VZV (gpELISA) Antibodies</title>
        <description>Mean VZV antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;5 gpELISA Units/mL) to VZV at baseline</description>
        <time_frame>6 weeks postvaccination</time_frame>
        <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Geometric Mean Titer of VZV (gpELISA) Antibodies</title>
          <description>Mean VZV antibody response at 6 weeks after vaccination for participants initially seronegative (&lt;5 gpELISA Units/mL) to VZV at baseline</description>
          <population>Analysis was performed on the per-protocol population, defined as all participants who had both pre- and post-vaccination blood samples, were seronegative at baseline, and followed all protocol procedures. Too few participants were enrolled in the study to perform non-inferiority analysis for this outcome measure.</population>
          <units>gpELISA units/mL</units>
          <param>Geometric Mean</param>
          <dispersion>90% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="10"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.4" lower_limit="6.9" upper_limit="15.5"/>
                    <measurement group_id="O2" value="11.9" lower_limit="7.6" upper_limit="18.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Measles-like Rash</title>
        <time_frame>Through 6 weeks postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Measles-like Rash</title>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Varicella-like Rash</title>
        <time_frame>Through 6 weeks postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Varicella-like Rash</title>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Rubella-like Rash</title>
        <time_frame>Through 6 weeks postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Rubella-like Rash</title>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Zoster-like Rash</title>
        <time_frame>Through 6 weeks postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Zoster-like Rash</title>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Any Systemic Adverse Experience</title>
        <description>An adverse experience is defined as any unfavorable and unintended change in the
structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. A systemic adverse experience is any adverse experience other than injection-site adverse experiences.</description>
        <time_frame>Through 6 weeks postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Any Systemic Adverse Experience</title>
          <description>An adverse experience is defined as any unfavorable and unintended change in the
structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. A systemic adverse experience is any adverse experience other than injection-site adverse experiences.</description>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.9"/>
                    <measurement group_id="O2" value="56.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Injection-site Adverse Experiences</title>
        <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. An injection-site adverse experience is an adverse experience that occurs at the injection site only.</description>
        <time_frame>Through 6 weeks postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Injection-site Adverse Experiences</title>
          <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. An injection-site adverse experience is an adverse experience that occurs at the injection site only.</description>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.4"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Injection-site Adverse Experiences</title>
        <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. An injection-site adverse experience is an adverse experience that occurs at the injection site only.</description>
        <time_frame>Through 5 days postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Injection-site Adverse Experiences</title>
          <description>An adverse experience is defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the study drug, whether or not considered related to the use of the product. Any worsening of a preexisting condition which is temporally associated with the use of the study drug is also an adverse experience. An injection-site adverse experience is an adverse experience that occurs at the injection site only.</description>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="0.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Percentage of Participants With Fever (≥101.0°F [38.3°C] Axillary or ≥103.0°F [39.4°C] Rectal)</title>
        <time_frame>Through 6 weeks postvaccination</time_frame>
        <population>The safety population included all participants who received study vaccination</population>
        <group_list>
          <group group_id="O1">
            <title>ProQuad™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
          <group group_id="O2">
            <title>M-M-R™ II and Varivax™</title>
            <description>Single subcutaneous 0.5 mL vaccination</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Fever (≥101.0°F [38.3°C] Axillary or ≥103.0°F [39.4°C] Rectal)</title>
          <population>The safety population included all participants who received study vaccination</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="13"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.7"/>
                    <measurement group_id="O2" value="12.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Through 28 days postvaccination</time_frame>
      <desc>The safety population included all participants who received study vaccination</desc>
      <group_list>
        <group group_id="E1">
          <title>ProQuad™</title>
          <description>Single subcutaneous 0.5 mL vaccination</description>
        </group>
        <group group_id="E2">
          <title>M-M-R™ II and Varivax™</title>
          <description>Single subcutaneous 0.5 mL vaccination</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 14.1</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="13"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Eye discharge</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="4" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pharyngotonsillitis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="3" subjects_affected="3" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Dermatitis atopic</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dermatitis diaper</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Pigmentation disorder</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E2" events="2" subjects_affected="2" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The sponsor must have the opportunity to review all proposed abstracts, manuscripts, or presentations regarding this study 60 days prior to submission for publication/presentation. Any information identified by the sponsor as confidential must be deleted prior to submission.</restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Formal testing of the study hypotheses was not possible because of low enrollment</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Senior Vice President, Global Clinical Development</name_or_title>
      <organization>Merck Sharp &amp; Dohme Corp.</organization>
      <phone>1-800-672-6372</phone>
      <email>ClinicalTrialsDisclosure@merck.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

